Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047674 | 0.82 | F10 (0.49) | F10 | |
| SCHEMBL5037598 | 0.81 | GPR119 (0.48) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5037600 | 0.81 | GPR119 (0.45) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3250796 | 0.79 | KDM1A (0.53) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1889385 | 0.74 | KDM1A (0.54) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL275404 | 0.73 | GPR119 (0.52) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3157462 | 0.73 | PDE4B (0.49) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL225777 | 0.73 | GPR119 (0.64) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL274655 | 0.73 | PDE4B (0.52) | GPR119PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL275205 | 0.73 | PDE4B (0.52) | GPR119PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | GPR119 2202/4885PDE4D 1815/4885PDE4A 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.